- Policy
- 3 drugs including Baricitinib are covered for COVID-19 tx
- by Kim, Jung-Ju Mar 12, 2021 06:22am
- Baricitinib, Corticosteroids, low-molecular weight heparin, and anticoagulants are covered to be used to COVID-19 confirmed patients. Kaletra (Lopinavir + ritonavir), Hydroxychloroquine, and Ribavirin were decided to be removed from the benefit. The MOHW decided to partially revise the notification of details on the application standar
- Company
- 3 companies have abandoned Pelubi's patent challenge
- by Kim, Jin-Gu Mar 12, 2021 06:22am
- Pharmaceutical companies that were trying to overcome the patent of Daewon's anti-inflammatory pain reliever Pelubi (Pelubiprofen) gave up. After Mother's and Hutecs voluntarily withdrew the request for a referee last year, Nexpharm was recently added, leaving only three of the six challengers. Some of the companies that voluntarily withdre
- Policy
- SK-manufactured AZ vaccines for export exceeds domestic use
- by Lee, Tak-Sun Mar 12, 2021 06:22am
- The volume of AstraZeneca COVID-19 vaccine manufactured at SK Bioscience Andong plant for export cleared for lot release has exceeded the volume for domestic supply. The AstraZeneca Korea COVID-19 Vaccine manufactured by SK Bioscience was authorized on Feb. 10, which the National Lot Release cleared 1.57 million doses of it on Feb. 17. S
- Opinion
- [Reporter's View] BINEX & NDMA Phobia
- by Lee, Jeong-Hwan Mar 12, 2021 06:21am
- It was said that it should never be done and it was malicious because it was deliberate. This is a concern from the National Assembly, the government, and the pharmaceutical industry looking at the situation of BINEX, which violated the pharmaceutical affairs law due to suspicion of manufacturing method and dosage manipulation, which is also
- InterView
- “High pressure and hopes in the policy affairs at KRPIA"
- by Eo, Yun-Ho Mar 11, 2021 06:07am
- Some say this is the era where policy comes first than an academy, and pricing is more important than an approval. The top priority for pharmaceutical companies in South Korea supplying new drug is the National Health Insurance (NHI) coverage. The era of highly expensive drug has emerged, while the government and pharmaceutical industry
- Policy
- Italy restricts export of AZ vaccine, including Korea
- by Lee, Tak-Sun Mar 11, 2021 06:07am
- It is an analysis that the EU's policy to restrict the export of the COVID-19 vaccine produced in Korea is highly likely to affect Korea. In particular, it is expected that the recent restriction on the export of AstraZeneca vaccine produced in Italy to Australia could directly affect the supply and demand of vaccines in Korea. This is be
- Company
- Genuone is licensed to manufacture Pariet
- by Kim, Jin-Gu Mar 11, 2021 06:07am
- Genuone received permission to change the manufacturer of Pariet (Rabeprazole) with an annual prescription amount of &8361;15 billion. This is the first achievement since its independence from Kolmar Korea and officially launched earlier this year. Genuone announced on the 9th that it has received permission to change the manufacturer of
- Company
- Tecentriq as liver cancer first-line treatment green lit
- by Mar 11, 2021 06:07am
- The South Korean health authority is seemingly giving a green light to an immunotherapy Tecentriq for its combination therapy as a first-line treatment in liver cancer. A pharmaceutical industry source reported on Mar. 9 that the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee approved of the clinical e
- Company
- Sales of erectile dysfunction generic drugs are increasing
- by An, Kyung-Jin Mar 11, 2021 06:06am
- Sales of the domestic erectile dysfunction treatment market decreased due to COVID-19. Sales declined, mainly for large items in the early days of the COVID-19 spread, and recovered after the second half of the year. Although sales of major products were low, generic products sold by Korean companies such as Hanmi and Chong Kun Dang were launche
- Policy
- MFDS reviews sales ban on Binex-manufactured generics
- by Lee, Jeong-Hwan Mar 10, 2021 06:27am
- The impact of the allegation on Binex manipulating the manufacturing method and active ingredient dosage in six drugs including antidiabetics and antidepressants is snowballing within the pharmaceutical industry. Source confirmed South Korea’s Ministry of Food and Drug Safety (MFDS) has started reviewing administrative measure to be o
